In summary, targeted therapies in lung cancer exemplify the paradigm of drugging specific oncogenic drivers such as EGFR, ALK, and KRAS, thereby providing substantial clinical benefit for well-defined molecular subgroups. This evidence concerns the gene ALK and lung carcinoma.